Opinions in Cardiology

What?

A publication in print about a first-in-class drug for the treatment of adults with hereditary amyloidosis who experience polyneuropathy.

Client

Alnylam BV

Indication

An orphan disease (hereditary transthyretin-mediated amyloidosis, hATTR)

Target audience

Cardiologists, neurologists

Goal

Introduction in the Netherlands of a new, first in class therapeutic (a so-called: ‘small interfering ribonucleic acid – RNAi’), patisiran, for the treatment of polyneuropathy as a consequence of hATTR

Solution

A publication featuring leading medical specialists discussing the added value and role of patisiran in the management of patients with this orphan disease.

Result

Contributed to a successful introduction to market of patisiran (Onpattro®, an RNAi)